
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Ober Gabelhorn glacier reveals remains of man missing for over three decades - 2
Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge - 3
Figure out How to Recognize Early Indications of Depressions - 4
In the background: Visiting Notable Film Areas All over the Planet - 5
Bullets in Luigi Mangione’s bag convinced police that he was UnitedHealthcare CEO killing suspect
Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
Astrophotographer captures spectacular photo of Antennae Galaxies dueling in deep space
Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
France to build new nuclear aircraft carrier, Macron says
Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
Make your choice for a definitive Christmas place to get-away!













